Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy
Eur Respir J
.
2021 Jun 10;57(6):2100166.
doi: 10.1183/13993003.00166-2021.
Print 2021 Jun.
Authors
Andrew P Hearn
1
2
,
Oliver D Hug
2
,
Ziana A Somani
2
,
Joanne Kavanagh
1
2
,
Grainne d'Ancona
1
,
Cris Roxas
1
,
Linda Green
1
,
Louise Thomson
1
,
Mariana Fernandes
1
,
Brian D Kent
1
3
4
,
Jaideep Dhariwal
1
,
Alexandra M Nanzer
1
,
David J Jackson
5
2
Affiliations
1
Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, London, UK.
2
School of Immunology and Microbial Sciences, King's College London, London, UK.
3
Dept of Respiratory Medicine, St James' Hospital, Dublin, Ireland.
4
School of Medicine, Trinity College Dublin, Dublin, Ireland.
5
Guy's Severe Asthma Centre, Guy's Hospital, Guy's and St Thomas' NHS Trust, London, UK David.Jackson@gstt.nhs.uk.
PMID:
33632798
DOI:
10.1183/13993003.00166-2021
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Anti-Idiotypic
Humans
Interleukin-5*
Receptors, Interleukin-5
Substances
Antibodies, Anti-Idiotypic
Interleukin-5
Receptors, Interleukin-5
anti-IgE antibodies